GENFLEET-B (02595.HK): buyback reaches 2,907,800 H shares
- The buybacks use the general mandate granted at the annual general meeting on 11 May 2026, after a voluntary announcement on the plan on 29 June 2026.
- Total repurchases reached 2,907,800 H shares as of 6 November 2026, about 0.757% of issued share capital at the announcement date.
NewTimeSpace News: On 9 November 2026, GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 02595) said that as of 6 November 2026 it had repurchased 2,907,800 H shares on the Stock Exchange in a series of buybacks, about 0.757% of its total issued share capital as at the announcement date.
The announcement shows the buybacks were made under the general mandate granted by shareholders at the annual general meeting on 11 May 2026, following the voluntary announcement on the 2026 buyback plan dated 29 June 2026. The company may assess market conditions and continue the plan. It cautioned that buybacks depend on the market and the board's discretion, with no assurance as to timing, volume or price, and urged shareholders to exercise caution when dealing in H shares.
- GENFLEET-B (02595.HK): GFH276 Combo Trials Cleared in China and Australia
- GENFLEET-B (02595.HK): First Clinical Data for Pan-RAS Inhibitor GFH276 Selected as ESMO LBA
- GENFLEET-B (02595.HK): Oral KRAS G12D Inhibitor Advances, 44% ORR in CRC Combo and 41% cORR in PDAC
- GENFLEET-B (02595.HK): GFH276 Data Selected as ESMO Late-Breaking Abstract
- GENFLEET-B (02595.HK): GFH375 Combo Proposed for BTD in Colorectal Cancer
